|Slideshows|July 17, 2018

Antipsychotics and Cardiometabolic Risk: New Study Sheds Light

Antipsychotic medications may not cause type 2 diabetes but a new review find the drugs may accelerate development of the disease. How can you protect your patients?

References:1. Whicher CA, Price HC, Holt RIG, et al. Mechanisms in endocrinology: Antipsychotic medication and type 2 diabetes and impaired glucose regulation. Eur J Endocrinol. 2018;178:R245-R258.2. National Institute for Health and Care Excellence. Psychosis and schizophrenia in children and young people: recognition and management. https://www.nice.org.uk/Guidance/CG155. Published January 2013. Accessed July 17, 2018.Â

Join thousands of clinicians staying current on new therapies, trial data, and expert insights—subscribe to HCPLive today.

Antipsychotics and Cardiometabolic Risk: New Study Sheds Light

Related Content

4 Endocrinology Headlines You Missed in August 2026

Tirzepatide Gets FDA Approval to Cut Cardiovascular Risk in Type 2 Diabetes

Diabetes Dialogue: Non-Invasive EEG Sensor Aims to Track Glucose in Real Time

Diabetes Dialogue: FreeStyle Libre Duo Cleared for Ketone Monitoring

Libre Duo 10 Day Authorized as First Glucose-Ketone Monitor for Diabetes

Latest CME

Cases and Conversations™: Mineralocorticoid Receptor Antagonists in Patients With HF—Augmenting Current Guidelines with Emerging Evidence

Hidradenitis Suppurativa: Diving Deeper Into Disease Pathogenesis, Severity Assessment, and Holistic Management Approaches

Burst CME CGM: Continuous Glucose Monitoring Considerations – Maximizing Quality of Life for Patients

Progress in Hyperlipidemia Management to Reduce ASCVD Risk: An Illustrated Update

Jersey City Psychiatry

2026 International Symposium of Gastrointestinal Oncology (ISGIO)

Navigating Advances in Neovascular Retinal Disease: Translating Evidence to Practice in AMD, DME, and RVO

(CME Track) Beyond the Collarette: Empowering Patients in the Management of Demodex Blepharitis

(COPE Track) Beyond the Collarette: Empowering Patients in the Management of Demodex Blepharitis

IgAN Case Files: Real Conversations, Evolving Evidence

Expert Illustrations & Commentaries™: Visualizing the Role of Dystrophin Dysregulation as a Therapeutic Target in Duchenne Muscular Dystrophy and MD STARnet

Shining a Light on an Ultra-Rare Disease – A Closer Look at Thymidine Kinase 2 Deficiency (TK2d)

Shining a Light on an Ultra-Rare Disease – A Closer Look at Thymidine Kinase 2 Deficiency (TK2d)

Identifying and Treating Generalized Myasthenia Gravis in the Modern Era

Addressing Unmet Needs for Patients With Spinal Muscular Atrophy—Understanding Patient Challenges and Management Approaches

Rewiring Recovery: Evidence-Based Approaches to Managing Chronic Inflammatory Demyelinating Polyneuropathy

Navigating Ocular Toxicities: A Multidisciplinary Roadmap for Managing Adverse Events in Targeted Cancer Therapy

5th Annual International Congress on Pediatric Oncology

(CME Track) Antibody–Drug Conjugates in Oncology: The Essentials of AE Management for Better Patient Outcomes

Clinical Consultations™: Tailoring Treatment for Cystic Fibrosis (CF) Across Life Stages and Evolving Health Needs

Clinical Consultations™: Tailoring Treatment for Cystic Fibrosis (CF) Across Life Stages and Evolving Health Needs

Clinical Consultations™: Tailoring Treatment for Cystic Fibrosis (CF) Across Life Stages and Evolving Health Needs

SimulatEd™: Partnering for Precision – A Framework for Personalized Care Planning in Acute Lymphoblastic Leukemia

Putting the Patient First in Acute Pain Management: The PA’s Guide to Incorporating Cutting-Edge Science Into Their Treatment Strategies

Putting the Patient First in Acute Pain Management: The PA’s Guide to Incorporating Cutting-Edge Science Into Their Treatment Strategies

Expert Illustrations & Commentaries™: Visualizing the Role of B Cells as Therapeutic Targets for Generalized Myasthenia Gravis

Rapid Reviews in Retina™: Emerging Updates from Fall 2025—Addressing the Wealth of New Data in Treatments for Neovascular Retinal Disease

Targeting the Cortisol Cascade: Diagnosis and Treatment Strategies in Patients with Hypertension

Targeting the Cortisol Cascade: Diagnosis and Treatment Strategies in Patients with Hypertension

Patient, Provider, and Caregiver Connection™: Individualizing Care in C3 Glomerulopathy – Understanding Patient Challenges and the Role of Innovative Treatment

Biomarker Testing in HER2+ GEA: Diagnosis and Treatment Implications

Navigating the Adverse Event Landscape in HER2+ GEA Therapy

Unlocking the Future of Glioma Care: Integrating Recent Advances to Personalize Treatment

Screening for Type 1 Diabetes and Delaying Its Onset—An Innovative View

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

Expert Illustrations & Commentary: Visualizing the Role of Novel Muscarinic Agents in the Management of Schizophrenia

Bridging Regional Challenges in Retinal Disease Management: Applying Advanced Anti-VEGF Therapy in Community Practice - NYC Metro

Bridging Regional Challenges in Retinal Disease Management: Applying Advanced Anti-VEGF Therapy in Community Practice - California

(CME Track) Tackling Oncologic Emergencies in Patients Treated With High-Dose Methotrexate

From Clue to Care: Rapid Recognition and Coordinated Management of Paraneoplastic LEMS in SCLC

Burst CME™: Optimal Management of Complications of Sickle Cell Disease

Burst CME™: Optimal Management of Complications of Sickle Cell Disease

Burst CME™: Transition from Pediatric to Adult Care in Sickle Cell Disease

Burst CME™: Transition from Pediatric to Adult Care in Sickle Cell Disease

Burst CME™: Disease-Modifying vs. Curative Therapy – Which Way to Go in Sickle Cell Disease?

Burst CME™: Disease-Modifying vs. Curative Therapy – Which Way to Go in Sickle Cell Disease?

Burst CME™ in Gaucher Disease: Patient Evaluation and Management

Optimizing Lipid-Lowering Strategies for ASCVD Risk Reduction: Bridging the Gap in Treatment Intensification

Collaborating Across the Continuum™: Integrating Novel Therapies Into Multidisciplinary Treatment Plans for Generalized Myasthenia Gravis

Burst CME™: Staying Informed and Up-To-Date on the Treatment of Lupus Nephritis

Burst CME™: Staying Informed and Up-To-Date on the Treatment of Lupus Nephritis

SimulatEd™: A Roadmap to Personalized Care Plans and Shared Decision-Making in Low-Grade Serous Ovarian Cancer

Community Collab™: Identifying the Role of Complement Inhibitors in the Management of Generalized Myasthenia Gravis

From Gene to Gut: Understanding TL1A’s Function in IBD Evolution

From Gene to Gut: Understanding TL1A’s Function in IBD Evolution

Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Community Collab: The Evolving Role of FcRN Inhibitors in the Management of Generalized Myasthenia Gravis (gMG)

The Presbyopia-Correcting and Toric IOL Playbook: Game-Changing Surgical Strategies to Enhance Patient Outcomes

Expert Illustrations & Commentary: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Cases and Conversations™: Navigating CKD and Heart Failure in T1D and T2D—Applying the Latest Guidelines and Evidence

Advances in™: Lipoprotein(a) as a Target for ASCVD Risk Reduction – Updates for Clinical Practice

When Mites Meet Their Match: Empowering Patients With Targeted Treatment for 𝘋𝘦𝘮𝘰𝘥𝘦𝘹 Blepharitis

Burst CME™: Burden of Sickle Cell Disease

Burst CME™: Burden of Sickle Cell Disease

Burst CME™: Recognizing Lupus Nephritis—From Timely Diagnosis to Appreciating the Underlying Mechanisms of Disease

Burst CME™: Recognizing Lupus Nephritis—From Timely Diagnosis to Appreciating the Underlying Mechanisms of Disease

Bridging Regional Challenges in Retinal Disease Management: Applying Advanced Anti-VEGF Therapy in Community Practice - Florida

The Rise of Novel HER2-Targeting Therapies in GEA: Mechanisms and Clinical Data

From Suspicion to Stabilization: Early Recognition and Treatment of Paraneoplastic LEMS

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

(Pharmacist Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia